Andrew is passionate about providing solid, commercially relevant intellectual property strategies to reduce environmental impact, improve human and animal health, develop high-tech devices and build infrastructure for the future, and more.
With a broad background in physics, biochemistry, and chemistry, Andrew has also completed a PhD in synthetic medicinal chemistry and post-doctoral studies in materials science.
Andrew is a council member of the New Zealand Institute of Patent Attorneys (NZIPA).Andrew is a proud father and when he gets a chance to stretch his legs away from his family he heads into the backcountry for rock climbing, mountain biking, tramping or mountaineering.
From his base in Christchurch, Andrew works with clients to develop intellectual property strategies that include patent landscaping and freedom to operate advice. Notable recent examples of this work include providing validity and infringement opinions in relation to generic medicines, infant milk formulae, remote sensing systems and metallurgical products in Australia and New Zealand.
Of course, Andrew also helps clients obtain their own patent and design rights. This extensive drafting and prosecution experience is grounded in a solid understanding of the ability to defend, enforce and challenge patent rights in Australia and New Zealand.
Notable recent examples of matters in which Andrew has been instrumental include:
Andrew was involved in the first decision under the post-Raising the Bar reforms in Australia and has an intimate knowledge of the new support and disclosure requirements under the Australian Patents Act 1990 and New Zealand Patents Act 2013.
Before joining the team at James & Wells, Andrew spent 8 years working with Australia’s largest specialist IP firm Davies Collison Cave, developing a strong foundation in Australian law and practice.
Andrew is a Master of Intellectual Property Law including studies in Licensing Law and Technology Transfer.
Andrew’s PhD in synthetic medicinal chemistry included devising a novel enantioselective synthesis of the potent antimitotic agent, and important anti-cancer precursor, (-)-podophyllotoxin. His studies also included elucidation of the biological activity and mechanism of action of structural analogs of podophyllotoxin. During that time Andrew provided advice to AstraZeneca in relation to a number of matters that were heard by the High Court (AstraZeneca AB v Apotex Pty Ltd; AstraZeneca AB v Watson Pharma Pty Ltd; AstraZeneca AB v Ascent Pharma Pty Ltd  HCA 30) and Full Court of the Federal Court of Australia (AstraZeneca AB v Apotex Pty Ltd (2014) 226 FCR 324).
He was awarded a post-doctoral fellowship in materials science which involved designing and synthesising new classes of amphiphilic molecules using controlled radical polymerization techniques and investigating the role that the molecules play in stabilizing high internal phase emulsions.